Cited 18 times in
Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정재용 | - |
dc.date.accessioned | 2014-12-20T16:49:49Z | - |
dc.date.available | 2014-12-20T16:49:49Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/93458 | - |
dc.description.abstract | PURPOSE: Leptomeningeal carcinomatosis is a devastating complication of malignant disease. In this study, we evaluated the safety and pharmacokinetics of intrathecally administered pemetrexed in rats. METHODS: Three levels of pemetrexed (0.3, 1, and 3 mg/kg) were administered to 15 rats per level (45 rats in total) twice a week for 2 weeks through specifically designed indwelling subarachnoid catheters. Presence of clinical and pathological neurotoxicity was evaluated. To evaluate the pharmacokinetics of pemetrexed, independent cohorts of 30 rats were treated with 1 mg/kg of pemetrexed and its concentration in cerebrospinal fluid (CSF) and blood was measured using UPLC/MS/MS. RESULTS: There were no cases of clinical or pathologic neurotoxicity after intrathecal administrations of pemetrexed at levels of 0.3 and 1 mg/kg; however, 5 of 15 (33%) rats died after administration of 3 mg/kg pemetrexed. The distribution/elimination of pemetrexed in CSF was best described by a two-compartment model, with initial and terminal half-lives of 0.43 and 1.43 h, respectively. The predicted maximal concentration in CSF was 588 μM, and high levels of pemetrexed appeared to be maintained for a long time. Area under the curve and volume of distribution at steady state were 560 μM h and 1.14 ml, respectively. CONCLUSIONS: The no observed adverse effect level of intrathecal administration of pemetrexed was 1 mg/kg in rats. At this level, therapeutically high and durable pemetrexed concentrations could be achieved. Based on these results, further research on intrathecal pemetrexed in humans or non-human primates should be considered. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 531~538 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/administration & dosage* | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/adverse effects* | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/analysis | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/pharmacokinetics | - |
dc.subject.MESH | Catheters, Indwelling | - |
dc.subject.MESH | Chromatography, High Pressure Liquid | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Drug Evaluation, Preclinical | - |
dc.subject.MESH | Glutamates/administration & dosage* | - |
dc.subject.MESH | Glutamates/adverse effects* | - |
dc.subject.MESH | Glutamates/analysis | - |
dc.subject.MESH | Glutamates/pharmacokinetics | - |
dc.subject.MESH | Guanine/administration & dosage | - |
dc.subject.MESH | Guanine/adverse effects | - |
dc.subject.MESH | Guanine/analogs & derivatives* | - |
dc.subject.MESH | Guanine/analysis | - |
dc.subject.MESH | Guanine/pharmacokinetics | - |
dc.subject.MESH | Half-Life | - |
dc.subject.MESH | Injections, Spinal | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Metabolic Clearance Rate | - |
dc.subject.MESH | Neurons/drug effects* | - |
dc.subject.MESH | Neurons/pathology | - |
dc.subject.MESH | Neurotoxicity Syndromes*/blood | - |
dc.subject.MESH | Neurotoxicity Syndromes*/cerebrospinal fluid | - |
dc.subject.MESH | Neurotoxicity Syndromes*/pathology | - |
dc.subject.MESH | No-Observed-Adverse-Effect Level | - |
dc.subject.MESH | Pemetrexed | - |
dc.subject.MESH | Rats | - |
dc.subject.MESH | Rats, Sprague-Dawley | - |
dc.subject.MESH | Subarachnoid Space | - |
dc.subject.MESH | Tandem Mass Spectrometry | - |
dc.subject.MESH | Tissue Distribution | - |
dc.subject.MESH | Toxicity Tests | - |
dc.title | Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pharmacology (약리학) | - |
dc.contributor.googleauthor | Jong-Mu Sun | - |
dc.contributor.googleauthor | Mi Hyun Nam | - |
dc.contributor.googleauthor | Jae Yong Chung | - |
dc.contributor.googleauthor | Bohee Im | - |
dc.contributor.googleauthor | Soo-Youn Lee | - |
dc.contributor.googleauthor | Youn-Lim Suh | - |
dc.contributor.googleauthor | Jin Seok Ahn | - |
dc.contributor.googleauthor | Keunchil Park | - |
dc.contributor.googleauthor | Myung-Ju Ahn | - |
dc.identifier.doi | 10.1007/s00280-010-1522-7 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03709 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 21107572 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-010-1522-7 | - |
dc.subject.keyword | Pemetrexed | - |
dc.subject.keyword | Leptomeningeal carcinomatosis | - |
dc.subject.keyword | Pharmacokinetics | - |
dc.subject.keyword | Toxicity | - |
dc.contributor.alternativeName | Chung, Jae Yong | - |
dc.contributor.affiliatedAuthor | Chung, Jae Yong | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 68 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 531 | - |
dc.citation.endPage | 538 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.68(2) : 531-538, 2011 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.